For: | Li J, Gao JZ, Du JL, Wei LX. Prognostic and clinicopathological significance of glypican-3 overexpression in hepatocellular carcinoma: A meta-analysis. World J Gastroenterol 2014; 20(20): 6336-6344 [PMID: 24876756 DOI: 10.3748/wjg.v20.i20.6336] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v20/i20/6336.htm |
Number | Citing Articles |
1 |
Rui Zhang, Li‑Jie Zhang, Mei‑Ling Yang, Lan‑Shan Huang, Gang Chen, Zhen‑Bo Feng. Potential role of microRNA‑223‑3p in the tumorigenesis of hepatocellular carcinoma: A comprehensive study based on data mining and bioinformatics. Molecular Medicine Reports 2017; doi: 10.3892/mmr.2017.8167
|
2 |
Antonio Junior Lepedda, Gabriele Nieddu, Zoi Piperigkou, Konstantina Kyriakopoulou, Nikolaos Karamanos, Marilena Formato. Circulating Heparan Sulfate Proteoglycans as Biomarkers in Health and Disease. Seminars in Thrombosis and Hemostasis 2021; 47(03): 295 doi: 10.1055/s-0041-1725063
|
3 |
Li Wang, Min Yao, Liu-Hong Pan, Qi Qian, Deng-Fu Yao. Glypican-3 is a biomarker and a therapeutic target of hepatocellular carcinoma. Hepatobiliary & Pancreatic Diseases International 2015; 14(4): 361 doi: 10.1016/S1499-3872(15)60396-4
|
4 |
Sayed Shahabuddin Hoseini, Nai-Kong V. Cheung. Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies. Cancer Letters 2017; 399: 44 doi: 10.1016/j.canlet.2017.04.013
|
5 |
Feng Gao, Heng-Kai Zhu, Yang-Bo Zhu, Qiao-Nan Shan, Qi Ling, Xu-Yong Wei, Hai-Yang Xie, Lin Zhou, Xiao Xu, Shu-Sen Zheng. Predictive value of tumor markers in patients with recurrent hepatocellular carcinoma in different vascular invasion pattern. Hepatobiliary & Pancreatic Diseases International 2016; 15(4): 371 doi: 10.1016/S1499-3872(16)60095-4
|
6 |
Gurjot Singh, Eric M Yoshida, Sahaj Rathi, Vladimir Marquez, Peter Kim, Siegfried R Erb, Baljinder S Salh. Biomarkers for hepatocellular cancer. World Journal of Hepatology 2020; 12(9): 558-573 doi: 10.4254/wjh.v12.i9.558
|
7 |
Md. Nahidul Wari, Archana George Vallonthaiel, Aijaz Ahmed, Deepali Saxena, Venkateswaran K. Iyer, Sandeep R. Mathur, Sandeep Agarwala, Sameer Bakhshi, V. Srinivas, P. Chattopadhyaya, Arundhati Sharma, S. Datta Gupta, Amit Dinda. Glypican-3 mRNA expression level in Wilms tumor: correlation with histological type, stage, and outcome. Pediatric Surgery International 2017; 33(6): 695 doi: 10.1007/s00383-017-4087-2
|
8 |
|
9 |
Dahai Xu, Chang Su, Liang Sun, Yuanyuan Gao, Youjun Li. Performance of Serum Glypican 3 in Diagnosis of Hepatocellular Carcinoma: A meta-analysis. Annals of Hepatology 2019; 18(1): 58 doi: 10.5604/01.3001.0012.7863
|
10 |
Felice De Stefano, Eduardo Chacon, Lilia Turcios, Francesc Marti, Roberto Gedaly. Novel biomarkers in hepatocellular carcinoma. Digestive and Liver Disease 2018; 50(11): 1115 doi: 10.1016/j.dld.2018.08.019
|
11 |
Pooja Basthi Mohan, Rajiv Lochan, Shiran Shetty. Biomarker in Hepatocellular Carcinoma. Indian Journal of Surgical Oncology 2024; 15(S2): 261 doi: 10.1007/s13193-023-01858-x
|
12 |
Yukihiro Haruyama, Kenji Yorita, Tetsuji Yamaguchi, Sachiko Kitajima, Jun Amano, Toshihiko Ohtomo, Akinobu Ohno, Kazuhiro Kondo, Hiroaki Kataoka. High preoperative levels of serum glypican‐3 containing N‐terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy. International Journal of Cancer 2015; 137(7): 1643 doi: 10.1002/ijc.29518
|
13 |
Jiliang Feng, Ruidong Zhu, Chun Chang, Lu Yu, Fang Cao, Guohua Zhu, Feng Chen, Hui Xia, Fudong Lv, Shijie Zhang, Lin Sun, Sheng-Nan Lu. CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection. PLOS ONE 2016; 11(3): e0151501 doi: 10.1371/journal.pone.0151501
|
14 |
Bita Moudi, Zahra Heidari, Hamidreza Mahmoudzadeh-Sagheb. Meta-analysis and systematic review of prognostic significance of Glypican-3 in patients with hepatitis B-related hepatocellular carcinoma. VirusDisease 2019; 30(2): 193 doi: 10.1007/s13337-019-00517-6
|
15 |
Cheng Chen, Kesang Li, Hua Jiang, Fei Song, Huiping Gao, Xiaorong Pan, Bizhi Shi, Yanyu Bi, Huamao Wang, Hongyang Wang, Zonghai Li. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma. Cancer Immunology, Immunotherapy 2017; 66(4): 475 doi: 10.1007/s00262-016-1949-8
|
16 |
Jiliang Feng, Ruidong Zhu, Dezhao Feng, Lu Yu, Dawei Zhao, Jushan Wu, Chunwang Yuan, Junmei Chen, Yan Zhang, Xiu Zheng. Prediction of Early Recurrence of Solitary Hepatocellular Carcinoma after Orthotopic Liver Transplantation. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-52427-8
|
17 |
Yasuhiro Shimizu, Shoichi Mizuno, Norihiro Fujinami, Toshihiro Suzuki, Keigo Saito, Masaru Konishi, Shinichiro Takahashi, Naoto Gotohda, Toshifumi Tada, Hidenori Toyoda, Takashi Kumada, Masahiro Miura, Kouzou Suto, Taiki Yamaji, Takahisa Matsuda, Itaru Endo, Tetsuya Nakatsura. Plasma and tumoral glypican‐3 levels are correlated in patients with hepatitis C virus‐related hepatocellular carcinoma. Cancer Science 2020; 111(2): 334 doi: 10.1111/cas.14251
|
18 |
Lorrane Viana, Rui Caetano Oliveira, Ricardo Martins, Henrique Alexandrino, Maria Augusta Cipriano, José Guilherme Tralhão. Prognostic Factors after Hepatectomy for Hepatocellular Carcinoma—The Importance of Pathological Immunophenotyping, the Steatohepatitic Subtype and the Impact of the Hepatic Pedicle Clamping. Gastrointestinal Disorders 2024; 6(2): 402 doi: 10.3390/gidisord6020027
|
19 |
Ewelina Rodakowska, Aurelia Walczak‑Drzewiecka, Marta Borowiec, Michal Gorzkiewicz, Joanna Grzesik, Marcin Ratajewski, Michal Rozanski, Jaroslaw Dastych, Krzysztof Ginalski, Leszek Rychlewski. Recombinant immunotoxin targeting GPC3 is cytotoxic to H466 small cell lung cancer cells. Oncology Letters 2021; 21(3) doi: 10.3892/ol.2021.12483
|
20 |
Jian Zhang, Manka Zhang, Huimin Ma, Xincheng Song, Lingling He, Xiaohui Ye, Xin Li. Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma. Medicine 2018; 97(24): e11130 doi: 10.1097/MD.0000000000011130
|
21 |
Antonio Junior Lepedda, Gabriele Nieddu, Nikos Karamanos, Marilena Formato. The Extracellular Matrix and the Tumor Microenvironment. Biology of Extracellular Matrix 2022; 11: 119 doi: 10.1007/978-3-030-99708-3_6
|
22 |
Yukihiro Haruyama, Hiroaki Kataoka. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma. World Journal of Gastroenterology 2016; 22(1): 275-283 doi: 10.3748/wjg.v22.i1.275
|
23 |
Huiying Zhang, Rui Ding, Daojun Chen. Value of miR-21 levels as potential biomarkers in the early diagnosis of hepatocellular carcinoma:a meta-analysis. Biomarkers 2021; 26(7): 586 doi: 10.1080/1354750X.2021.1955976
|
24 |
Umberto Cillo, Tommaso Giuliani, Marina Polacco, Luz Maria Herrero Manley, Gino Crivellari, Alessandro Vitale. Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World Journal of Gastroenterology 2016; 22(1): 232-252 doi: 10.3748/wjg.v22.i1.232
|
25 |
Said A. Mohamed, Al-Sayed M.I. Tealeb. The role of heat shock protein 70 and glypican 3 expression in early diagnosis of hepatocellular carcinoma. Egyptian Journal of Pathology 2022; 42(2): 112 doi: 10.4103/egjp.egjp_21_22
|
26 |
Ran Xue, Jiliang Feng, Qinghua Meng, Fudong Lv, Yueke Zhu, Hongwei Yu, Shijie Zhang, Chenzhao Song, Lin Sun, Zhujun Yue, Shuai Feng, Ruiwen Che, Qian Xiang, Xiaodan Jing. The significance of glypican‐3 expression profiling in the tumor cellular origin theoretical system for hepatocellular carcinoma progression. Journal of Gastroenterology and Hepatology 2017; 32(8): 1503 doi: 10.1111/jgh.13736
|
27 |
JIAN-ZHI GAO, JIA LI, JING-LI DU, XIAO-LEI LI. Long non-coding RNA HOTAIR is a marker for hepatocellular carcinoma progression and tumor recurrence. Oncology Letters 2016; 11(3): 1791 doi: 10.3892/ol.2016.4130
|
28 |
Min Yao, Li Wang, Miao Fang, Wenjie Zheng, Zhizhen Dong, Dengfu Yao. Advances in the study of oncofetal antigen glypican-3 expression in HBV-related hepatocellular carcinoma. BioScience Trends 2016; 10(5): 337 doi: 10.5582/bst.2016.01176
|